In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Celltech Chiroscience PLC acquires Medeva PLC for $914mm

Executive Summary

In a stock swap, Celltech Chiroscience PLC (CCP) has acquired competitor Medeva PLC, exchanging 34 of its shares for every 100 Medeva shares held. Based on CCP's closing price of $7.87 the day before the announcement, it is paying $2.67 per share of Medeva, representing about a (pr)16% premium to Medeva's pre-announcement price,valuing the transaction at $914mm (UK563mm). CCP shareowners will hold 56% of the combined entity--which will be called the Celltech Group PLC--with Medeva holding the rest. Peter Fellner, Celltech's CEO, will serve in the same capacity at the new company, which will have a $2.1bn pro-forma market cap.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Stock

Related Companies